Flexibility and inhibitor binding in cdc25 phosphatases

Guilherme Menegon Arantes1

  • 1Instituto de Química, Universidade de São Paulo, Av Lineu Prestes 748, 05508-900 São Paulo, Brasil. garantes@iq.usp.br

Proteins
|August 27, 2010
PubMed

Insights

Cdc25B phosphatases, key in cell cycle regulation and cancer, exhibit C-terminal flexibility. This flexibility creates unique binding sites for inhibitors, crucial for developing new anti-cancer drugs.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Pharmacology

Background:

  • Cdc25 phosphatases are crucial regulators of the cell cycle and are targeted for anti-cancer therapies.
  • Existing structural data for Cdc25 phosphatases are limited to apo- or sulfate-bound crystal structures of the catalytic domain.

Purpose of the Study:

  • To investigate the structural flexibility of Cdc25B, particularly its C-terminus, in solution.
  • To analyze the impact of this flexibility on the binding of small molecule inhibitors to Cdc25B.
  • To identify potential binding sites and interaction modes for rational drug design.

Main Methods:

  • Molecular dynamics simulations and bioinformatic analysis to model Cdc25B conformational ensembles.
  • Development of three structural models with varying flexibility, including an equilibrium ensemble.
  • Flexible docking, clustering, and linear interaction energy approximation for binding free energy calculations.

Main Results:

  • The C-terminus of Cdc25B (last 30-40 residues) is partially unfolded or disordered in solution.
  • Two distinct binding sites for small molecule inhibitors were identified: one adjacent to and one on top of the active site.
  • Increased receptor flexibility led to a greater diversity of interaction modes and the formation of transient cavities.

Conclusions:

  • Cdc25B's C-terminal flexibility significantly influences inhibitor binding, revealing previously inaccessible binding pockets.
  • Understanding these flexible binding mechanisms is vital for designing more effective anti-cancer drugs targeting Cdc25 phosphatases.
  • The study provides insights into small molecule complexation with partially disordered proteins.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.